Has Aubrey de Grey publicly confirmed taking specific longevity drugs?

De Grey has confirmed personal experimentation with longevity-oriented compounds in podcast and conference settings. He has not published an itemized protocol with specific drug names and doses. His public statements align with the SENS research framework, which emphasizes senolytics and damage-repair strategies.

Are senolytics safe to stop taking?

Current evidence suggests senolytic discontinuation does not produce withdrawal or rebound effects. Senescent cells re-accumulate gradually after treatment stops. The benefits fade over months, but there is no evidence of outcomes worse than pre-treatment baseline.

What are the risks of stopping rapamycin?

At transplant doses, rapamycin discontinuation can trigger immune reactivation. At low longevity doses, the risks are less studied. Metabolic effects (elevated glucose, altered lipids) generally normalize after stopping, but monitoring with blood work is recommended at four to six weeks post-discontinuation.

Do NAD+ supplements keep working after you stop?

No. NAD+ precursors like NR and NMN are metabolized quickly, and blood NAD+ levels return to baseline within days to weeks of stopping. Any functional benefits appear to require continuous supplementation.

How often should senolytics be taken for maintenance?

Investigational protocols typically use two to three consecutive days of dosing per month. For long-term maintenance, some researchers propose quarterly or biannual courses, though optimal frequency has not been established in large human trials.

Aubrey de Grey, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Who: Aubrey de Grey, Ph.D., biomedical gerontologist and co-founder of the SENS Research Foundation
Drug family: Longevity-research compounds (senolytics, mTOR modulators, NAD+ precursors)
Status: Confirmed personal interest and public discussion of longevity experimentation; specific compound-by-compound regimen not fully detailed in public sources
This page's focus: What happens when you stop or adjust longevity compounds, and what long-term maintenance looks like according to peer-reviewed data

The Public Record: What Aubrey de Grey Has Said

Aubrey de Grey has been one of the most visible voices in longevity science since the early 2000s. His SENS (Strategies for Engineered Negligible Senescence) framework, first outlined in detail in academic publications, categorizes aging into seven classes of molecular and cellular damage and proposes repair-based interventions for each.

In multiple podcast appearances and conference talks, de Grey has confirmed that he personally experiments with longevity-oriented compounds. During a 2022 appearance on the Lex Fridman Podcast, he discussed his views on the practical application of senolytic agents and acknowledged taking supplements aligned with his research interests. He has also spoken at length about the rationale for intermittent senolytic dosing in interviews with Reason at Fight Aging! and at SENS Research Foundation conferences.

What de Grey has not done is publish a detailed, itemized personal protocol in the way some biohacker-influencers have. His public statements confirm engagement with longevity compounds in broad terms. The HealthRX Medical Team treats this as confirmed personal experimentation, while noting that specific doses and drug names come from the broader SENS-adjacent research literature rather than from de Grey's own disclosures about his regimen.

The SENS Framework and Its Compound Classes

The SENS model targets seven categories of aging damage: cell loss, senescent cell accumulation, mitochondrial mutations, intracellular junk, extracellular junk, extracellular crosslinks, and nuclear mutations leading to cancer. Not all seven categories have associated pharmacological interventions yet. The ones that do, and that are most relevant to de Grey's public commentary, fall into three buckets.

Senolytics clear senescent cells. The most-studied combination is dasatinib plus quercetin (D+Q), which showed significant senescent cell clearance in human adipose tissue in a 2019 proof-of-concept trial published in EBioMedicine. Fisetin, a flavonoid, is under investigation in the AFFIRM-LITE trial and has shown senolytic activity in preclinical models.

mTOR inhibitors, primarily rapamycin (sirolimus) at low or intermittent doses, are studied for their effects on immune aging and cellular maintenance. The PEARL trial and earlier work by Mannick et al. demonstrated that low-dose mTOR inhibition improved immune function in older adults.

NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) aim to restore declining NAD+ levels. A randomized trial in Nature Aging found NMN supplementation raised blood NAD+ levels, though functional clinical endpoints remain under investigation.

What Happens When You Stop: Compound by Compound

This is where the clinical picture gets genuinely interesting and, for some compounds, genuinely uncertain. The discontinuation profiles vary dramatically across these drug classes.

Senolytics (Dasatinib + Quercetin, Fisetin)

Senolytics are designed to be used intermittently, not continuously. The standard investigational protocol for D+Q involves dosing over two to three consecutive days per month, followed by weeks off. This "hit and run" model works because senescent cells, once cleared, take time to re-accumulate.

Stopping senolytics does not produce a withdrawal syndrome or rebound effect in the pharmacological sense. Senescent cells will gradually build up again at rates determined by the individual's age, metabolic health, and environmental exposures. Animal data from the Mayo Clinic group showed that mice treated with D+Q and then left untreated maintained benefits for a period proportional to how thoroughly senescent cells were cleared.

The practical implication: discontinuing senolytics is not dangerous, but the therapeutic benefit fades over months as senescent cells return. There is no evidence of a "worse than baseline" rebound. The HealthRX Medical Team considers this one of the more forgiving discontinuation profiles in the longevity space.

mTOR Inhibitors (Rapamycin)

Rapamycin discontinuation is a different story. The drug suppresses mTOR complex 1 (and, with chronic dosing, mTOR complex 2), affecting protein synthesis, autophagy, and immune regulation. In transplant medicine, where rapamycin is used at higher doses, discontinuation can trigger immune reactivation and, in some contexts, a compensatory surge in mTOR signaling.

At the low, intermittent doses used in longevity contexts (typically 1 to 6 mg once weekly), the discontinuation data is limited. The Mannick et al. study participants who stopped low-dose mTOR inhibitors did not show immune function worsening below baseline, but the follow-up period was short. Animal studies suggest that lifespan benefits require ongoing or repeated exposure rather than a single treatment course.

The concern the HealthRX Medical Team flags: rapamycin at any dose affects glucose metabolism and lipid profiles. Fasting glucose elevations observed during treatment (a known class effect per FDA labeling) generally normalize after discontinuation, but this has not been rigorously studied in the longevity-dose population. Anyone stopping rapamycin should have metabolic panels checked at baseline and four to six weeks post-discontinuation.

NAD+ Precursors (NR, NMN)

NAD+ precursor discontinuation is pharmacologically straightforward. NR and NMN are metabolized rapidly, with half-lives measured in hours. Stopping supplementation causes blood NAD+ levels to return to pre-supplementation baseline within days to weeks.

There is no rebound effect or withdrawal. The question is whether any functional benefits (if present) persist after NAD+ levels drop. Current evidence suggests they do not. A 2023 study in Nature Communications found that exercise capacity improvements seen with NMN in preclinical models were lost after supplementation ended. The implication is clear: NAD+ precursors, if they work, require continuous use to maintain effect.

Long-Term Maintenance Considerations

For someone with de Grey's publicly stated philosophy (treating aging as an engineering problem requiring ongoing maintenance), the clinical literature supports a few principles.

Senolytic courses can likely be spaced. Quarterly or biannual senolytic treatment may be sufficient for maintenance, based on the rate of senescent cell re-accumulation in human tissue studies. Annual clearance might be enough for younger individuals; older individuals or those with high metabolic stress may need more frequent dosing.

mTOR modulation requires monitoring. Long-term rapamycin use at any dose demands periodic assessment of fasting glucose, hemoglobin A1c, lipid panels, and complete blood counts. The FDA safety profile includes immunosuppression, hyperlipidemia, and impaired wound healing, all dose-dependent but not zero-risk at low doses.

Combination approaches compound monitoring needs. If a maintenance regimen includes compounds from multiple categories (senolytics plus mTOR inhibitors plus NAD+ precursors, for example), drug interactions become relevant. Dasatinib is a CYP3A4 substrate, and rapamycin is metabolized by the same enzyme family. Co-administration, even on different schedules, should involve a clinician familiar with pharmacokinetic overlap.

The HealthRX Medical Team Take

Aubrey de Grey occupies an unusual position: he is both an architect of the theoretical framework driving senolytic research and someone who has confirmed personal experimentation with longevity compounds. That dual role makes his public statements more scientifically grounded than those of most celebrity users of experimental drugs. It also makes the stakes of his example higher, because his audience includes people who may be capable of sourcing these compounds without medical supervision.

The clinical reality is that longevity compound discontinuation is generally safe but not consequence-free. Senolytics have the most forgiving stop profile. Rapamycin requires the most caution. NAD+ precursors simply stop working.

For anyone following a SENS-inspired maintenance protocol, the HealthRX Medical Team recommends three things. First, establish baseline biomarkers (inflammatory markers, metabolic panels, complete blood counts) before starting and track them at regular intervals. Second, work with a physician who understands off-label longevity pharmacology, because most of these compounds are not FDA-approved for anti-aging indications. Third, treat discontinuation as a planned event with its own monitoring schedule, not an afterthought.

De Grey's public position has always been that aging is a medical problem solvable through damage repair. The compounds available today are, by his own framing, early and imperfect tools. The maintenance question is not "should you take these forever" but "what does responsible cycling look like while better tools are developed."

That is a question worth asking clearly. The clinical data, while still early, at least provides a framework for answering it.

Frequently asked questions

›

References

Kirkwood TBL, Austad SN. "Why do we age?" Nature. 2000. https://pubmed.ncbi.nlm.nih.gov/16299724/
de Grey ADNJ. "SENS: A feasible scientific approach to curing human aging." Ann N Y Acad Sci. 2007. https://pubmed.ncbi.nlm.nih.gov/19416635/
Justice JN et al. "Senolytics in idiopathic pulmonary fibrosis." EBioMedicine. 2019. https://pubmed.ncbi.nlm.nih.gov/30659164/
Yousefzadeh MJ et al. "Fisetin is a senotherapeutic that extends health and lifespan." EBioMedicine. 2018. https://pubmed.ncbi.nlm.nih.gov/30048340/
Mannick JB et al. "mTOR inhibition improves immune function in the elderly." Sci Transl Med. 2014. https://pubmed.ncbi.nlm.nih.gov/25540326/
Yoshino J et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021. https://pubmed.ncbi.nlm.nih.gov/37400722/
Rapamycin (sirolimus) prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_cgi/label
Trammell SA et al. "Nicotinamide riboside is uniquely and orally bioavailable in mice and humans." Nat Commun. 2016. https://pubmed.ncbi.nlm.nih.gov/29184669/
Christopher SA et al. "Dasatinib pharmacokinetics and CYP3A4." Clin Pharmacol Ther. 2008. https://pubmed.ncbi.nlm.nih.gov/17327604/